Compounds > dalteparin
Page last updated: 2024-10-18

dalteparin and Benign Neoplasms

dalteparin has been researched along with Benign Neoplasms in 177 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Research Excerpts

ExcerptRelevanceReference
" We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study."9.51Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022)
" We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old."9.51A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022)
"Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio."9.41Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021)
"We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study."9.41Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021)
"Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding."9.34Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020)
"In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism' (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients with cancer."9.34Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. ( de Jong, LA; Hulst, MV; Postma, MJ; van der Velden, AWG, 2020)
"To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively."9.30Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."9.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding."9.27Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018)
"The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism."9.22Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016)
"The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)."9.20Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015)
"Major bleeding was less frequent during dalteparin therapy beyond 6 months."9.20Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015)
"Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding."9.20Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015)
"We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)."9.14Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009)
"Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial."9.11Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005)
"Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients."9.10Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003)
"To determine the effect and safety of sequential treatment with the low-molecular-weight heparin dalteparin and the direct oral anticoagulants rivaroxaban in patients with cancer- associated venous thromboembolism (VTE)."8.02Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism. ( Chen, L; Chen, Q; Zhu, M; Zhuang, Z, 2021)
"Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy."7.88Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018)
" The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban."7.85Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017)
"Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2."7.11Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022)
"Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence."6.90Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019)
"Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7."6.84Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017)
" This analysis supports dosing patients with renal impairment in accordance with patients with normal renal function; however, anti-Xa monitoring could be considered to further support safety in selected patients, particularly those with very severe renal impairment."6.82A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. ( Abreu, P; Feugère, G; Heissler, J; Jen, F; Ruiz, MT; Woodruff, S, 2016)
"Rivaroxaban is a potential option for patients with cancer and VTE."6.58Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis. ( Chen, D; Xing, J; Yin, X, 2018)
"Cancer is a major risk factor for the development of venous thromboembolism (VTE)."6.44Management of venous thromboembolism in patients with cancer: role of dalteparin. ( Linkins, LA, 2008)
" We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study."5.51Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Connors, JM; Franco, L; Gussoni, G; Hamulyak, EN; Lambert, C; Mahé, I; Muñoz, A; Suero, MR; Torbicki, A, 2022)
"In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months."5.51Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. ( Aquilanti, S; Bertoletti, L; Brebion, N; Brisot, D; Bura-Rivière, A; Burnod, A; Charles-Nelson, A; Chatellier, G; Constans, J; Couturaud, F; Elias, A; Falvo, N; Girard, P; Grange, C; Laporte, S; Mahé, I; Meyer, G; Mismetti, P; Pernod, G; Planquette, B; Ray, V; Roy, PM; Sanchez, O; Sevestre, MA; Timar-David, M, 2022)
" We conducted a prospective, multicenter, open-label trial (NCT00952380) on dose-finding, safety, and efficacy (measured by 90-day risks of clinically relevant bleeding [CRB] and symptomatic recurrent VTE [srVTE]) of twice-daily subcutaneous dalteparin for acute VTE treatment in patients ≤18 years old."5.51A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. ( Goldenberg, NA; Hartman, LR; Jani, D; Nurmeev, I; Sherman, N; Svirin, P; Wolter, KD; Yan, JL, 2022)
"Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome."5.51Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019)
"The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)."5.48Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018)
"Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio."5.41Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021)
"We evaluated the effects of concomitant administration of anticancer agents on recurrent VTE, major bleeding and death in patients with cancer-associated VTE randomised to receive apixaban or dalteparin in the Caravaggio study."5.41Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. ( Agnelli, G; Bauersachs, R; Becattini, C; Huisman, MV; Mandalà, M; Munoz, A; Verso, M; Vescovo, G, 2021)
"Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding."5.34Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020)
"In the 'Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism' (SELECT-D) trial, rivaroxaban showed relatively low venous thromboembolism (VTE) recurrence but higher bleeding compared with dalteparin in patients with cancer."5.34Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. ( de Jong, LA; Hulst, MV; Postma, MJ; van der Velden, AWG, 2020)
"To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively."5.30Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. ( Bott-Kitslaar, DM; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; Mcbane, RD; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2019)
"In patients with active cancer and acute venous thromboembolism (VTE), the low-molecular-weight-heparin (LMWH) dalteparin is more effective than vitamin K antagonist (VKA) in reducing the risk of recurrent venous thromboembolism (rVTE) without increasing the risk of bleeding."5.30Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. ( Abreu, P; Carrier, M; Feugère, G; Heissler, J; Lee, AYY; Woodruff, S, 2019)
"Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality."5.30Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999)
"Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding."5.27Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. ( Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, MA; Kakkar, AK; Kovacs, MJ; Mercuri, MF; Meyer, G; Raskob, GE; Segers, A; Shi, M; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Yeo, E; Zhang, G; Zwicker, JI, 2018)
"In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in 1,050 patients with cancer-associated VTE."5.27Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. ( Beyer-Westendorf, J; Büller, HR; Carrier, M; Di Nisio, M; Garcia, D; Grosso, M; Hernandez, CR; Kakkar, AK; Kraaijpoel, N; Mercuri, MF; Middeldorp, S; Mulder, FI; Raskob, GE; Santamaria, A; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Wang, TF; Weitz, JI; Zhang, G; Zwicker, JI, 2018)
"The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous thromboembolism."5.22Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. ( Ageno, W; Büller, HR; Di Nisio, M; Pap, AF; Rutjes, AW, 2016)
" Direct comparisons show that DOACs significantly decrease recurrent venous thromboembolism (VTE) events compared with dalteparin (odds ratio [OR], 0."5.22Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. ( Badgett, RG; Bryce, AH; Fuentes, HE; He, H; Liu, H; Marshall, AL; McBane, RD; Montori, V; Murad, MH; Naqvi, SAA; Padranos, L; Riaz, IB; Sipra, QR; Tafur, AJ; Vandvik, PO; Wysokinski, WE, 2022)
"The AMPLIFY trial compared apixaban with enoxaparin followed by warfarin for the treatment of acute venous thromboembolism (VTE)."5.20Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. ( Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lee, TC; Pak, R; Raskob, GE; Weitz, JI; Yamabe, T, 2015)
"Major bleeding was less frequent during dalteparin therapy beyond 6 months."5.20Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. ( Bergqvist, D; Francis, CW; Goldhaber, SZ; Huisman, MV; Kakkar, AK; Kessler, CM; Kovacs, MJ; Monreal, M; Ortel, TL; Pabinger, I; Spyropoulos, AC; Turpie, AG, 2015)
"Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding."5.20Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015)
"We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT)."5.14Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. ( Balestreri, L; Bertuzzi, CA; Bidoli, E; De Cicco, M; Fabiani, F; Fantin, D; Malafronte, M; Matovic, M; Morassut, S; Pacenzia, R; Steffan, A; Veronesi, A, 2009)
"Survival data were examined in a posthoc analysis in patients with solid tumors and venous thromboembolism who were randomly assigned to dalteparin or a coumarin derivative for 6 months in a multicenter, open-label, randomized, controlled trial."5.11Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. ( Baker, RI; Bowden, C; Gent, M; Julian, JA; Kakkar, AK; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2005)
"Warfarin at a fixed, very low dose and nadroparin at a fixed, prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients."5.10Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. ( Buchmüller-Cordier, A; Charlet, V; Decousus, H; Dutrey-Dupagne, C; Fournel, P; Jacquin, JP; Laporte, S; Mille, D; Mismetti, P, 2003)
"In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding."5.10Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003)
" Although low-molecular-weight heparin and direct oral anticoagulants, such as apixaban and rivaroxaban, have been evaluated for the prevention of catheter thrombosis, their efficacy remains uncertain."4.31Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. ( Fredenburgh, JC; Guan, Z; Hussain, RH; Jaffer, IH; Wang, R; Weitz, JI, 2023)
"We evaluated the risks of VTE recurrence and treatment-related major bleeding according to the cancer stage in patients with VTE and solid cancer randomised to apixaban or dalteparin in the Caravaggio study."4.12Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. ( Agnelli, G; Becattini, C; Brenner, B; Cohen, AT; Connors, JM; Gussoni, G; Huisman, M; Munoz, A; Sanchez, O; Verso, M, 2022)
"To determine the effect and safety of sequential treatment with the low-molecular-weight heparin dalteparin and the direct oral anticoagulants rivaroxaban in patients with cancer- associated venous thromboembolism (VTE)."4.02Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism. ( Chen, L; Chen, Q; Zhu, M; Zhuang, Z, 2021)
"Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy."3.88Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin. ( Kettle, JK; Ludwig, SL; Nicklaus, MD, 2018)
" The aim of this study was to determine the efficacy and safety, using the incidence of recurrent symptomatic VTE and major bleeding, respectively, throughout the treatment with rivaroxaban."3.85Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience. ( Bomfim, GAZ; Cavalcante, RN; Centofanti, G; Fonseca, IYI; Krutman, M; Nishinari, K; Pignataro, BS; Ramacciotti, E; Sanches, SM; Teivelis, MP; Wolosker, N; Yazbek, G, 2017)
"The risk of late thrombosis and pulmonary embolism is discussed from pathogenetic factors and data on frequencies of thromboembolic complications in the literature."3.78Prolonged prophylaxis against postoperative venous thromboembolism. ( Bergqvist, D, 1996)
"In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin."3.75Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009)
"In a recent randomised trial (CLOT [Comparison of Low molecular weight heparin versus Oral anticoagulant Therapy for long term anticoagulation in cancer patients with venous thromboembolism]), which evaluated secondary prophylaxis of venous thromboembolism (VTE) in cancer patients, dalteparin reduced the relative risk of recurrent VTEs by 52% compared with oral anticoagulation therapy (p = 0."3.73Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. ( Crowther, M; Dranitsaris, G; Vincent, M, 2006)
" The rate of thrombosis rose to 10% (6/60) if no high-risk dose of dalteparin was applied subcutaneously."3.72Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing. ( Fung, S; Janssen, D; Kotowa, W; Lersch, C, 2004)
" The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight."3.72Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004)
"Advanced or metastatic cancer was the only independent predictor of major bleeding (HR=2."3.11Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial ( Agnelli, G; Bauersachs, R; Becattini, C; Bertoletti, L; Brenner, B; Cohen, A; Connors, JM; Manfellotto, D; Maraziti, G; Sanchez, A, 2022)
"Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment."3.11Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study. ( Charalambakis, N; Kosmas, C; Lianos, E; Liatsos, AN; Mazlimoglou, E; Papageorgiou, G; Pouliakis, A; Simeonidis, D; Xynogalos, S; Ziras, N, 2022)
"Adult patients with cancer at the time they develop thrombosis."3.01Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. ( Eckman, MH; Gulati, S, 2023)
"Compared to cancer patients with symptomatic VTE, those with incidental VTE have different clinical features at presentation, with a numerically lower incidence of recurrent VTE and a numerically higher incidence of major bleeding."3.01Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. ( Agnelli, G; Bauersachs, R; Becattini, C; Cohen, AT; Connors, JM; Dentali, F; Falvo, N; Giustozzi, M; Huisman, M; Ruperez Blanco, AB; Szmit, S, 2021)
"Hospitalized patients with cancer are at an increased risk of developing venous thromboembolism (VTE)."2.94Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. ( Bauer, KA; Bockorny, B; Joyce, R; Khorana, AA; Neuberg, D; Peereboom, D; Puligandla, M; Roopkumar, J; Schlechter, BL; Sharda, AV; Zwicker, JI, 2020)
"Recommended treatment for cancer-associated thrombosis is 3-6 months of low-molecular-weight heparin."2.90Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. ( Date, K; Hutchinson, A; Johnson, MJ; Maraveyas, A; Rees, S; Young, A, 2019)
"Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence."2.90Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019)
"Essentials Cancer patients receiving anticoagulants for venous thromboembolism have an elevated bleeding risk."2.87Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018)
"RI in patients with cancer-associated thrombosis on anticoagulation was associated with a statistically significant increase in recurrent VTE and major bleeding, but no significant increase in CRB or mortality."2.87Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2018)
"Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in dalteparin arm (N=7 versus 1 on observation) (HR=7."2.84Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. ( Baran, A; Carrier, M; Francis, CW; Hobbs, S; Iyer, R; Kaproth-Joslin, K; Khorana, AA; Kuderer, NM; Lyman, GH; Ortel, TL; Peterson, D; Rubens, D; Wun, T, 2017)
" This analysis supports dosing patients with renal impairment in accordance with patients with normal renal function; however, anti-Xa monitoring could be considered to further support safety in selected patients, particularly those with very severe renal impairment."2.82A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. ( Abreu, P; Feugère, G; Heissler, J; Jen, F; Ruiz, MT; Woodruff, S, 2016)
"A total of 10 cancer patients with VTE treated with the LMWH enoxaparin at a standard dose of 1 mg/kg every 12 h were enrolled."2.80Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. ( Gabizon, AA; Na'amad, M; Nasser, NJ; Weinberg, I, 2015)
"The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer."2.80Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015)
"Patients receiving chemotherapy for cancer are at increased risk for venous thromboembolism."2.77Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. ( Agnelli, G; Chaudhari, U; Fisher, W; George, DJ; Kakkar, AK; Lassen, MR; Lawson, F; Mismetti, P; Mouret, P; Turpie, AG, 2012)
"Major bleeding was comparable and minor bleedings (0."2.76Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. ( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011)
"Non-surgical cancer patients are at high thrombotic risk."2.75The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. ( Eichinger, S; Kaider, A; Kranz, A; Kyrle, PA; Quehenberger, P; Schmid, R; Traby, L, 2010)
" After initial LMWH, patients received 6 months of treatment with full therapeutic dosage of tinzaparin or acenocoumarol."2.74A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. ( Bonell, A; Cairols, MA; Colomé, E; Lapiedra, O; Martí, X; Romera, A; Vila-Coll, R, 2009)
"Dalteparin was demonstrated to be safe over 16 weeks of treatment in these patients."2.72Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. ( Abecasis, NG; Baronius, W; Biakhov, M; Fountzilas, G; Garin, A; Giorgetti, C; Irwin, D; Karthaus, M; Kretzschmar, A; Kröning, H; Marschner, N; Reichardt, P; Slabber, C; Steger, GG; Südhoff, T, 2006)
"Subjects were patients with cancer and acute symptomatic proximal-vein thrombosis."2.72Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. ( Brant, RF; Burke, N; Cook, R; Dear, R; Hull, RD; Mah, AF; Pineo, GF; Poon, MC; Raskob, G; Solymoss, S; Wong, T, 2006)
"Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival."2.71The effect of low molecular weight heparin on survival in patients with advanced malignancy. ( Bos, MM; Büller, HR; Klerk, CP; Lensing, AW; Otten, HM; Piovella, F; Prandoni, P; Prins, MH; Richel, DJ; Smorenburg, SM; van Tienhoven, G, 2005)
"The primary end points of the study were deep vein thrombosis (DVT), confirmed by venography of the CVC limb performed 6 weeks after randomization, or clinically overt pulmonary embolism, confirmed by objective testing during the study drug administration."2.71Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. ( Ageno, W; Agnelli, G; Bazzan, M; Bertoglio, S; Di Somma, FC; Imberti, D; Mosca, S; Naglieri, E; Paoletti, F; Parise, P; Quintavalla, R; Santoro, A; Sorarù, M; Verso, M, 2005)
"Fatal pulmonary embolism was significantly more frequent in cancer patients (0."2.71Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. ( Encke, A; Haas, S; Kakkar, AK; Wolf, H, 2005)
"Patients with advanced malignancy (N = 385) were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year."2.71Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). ( Kadziola, Z; Kakkar, AK; Lemoine, NR; Levine, MN; Low, V; Patel, HK; Quigley, M; Rustin, G; Thomas, M; Williamson, RC, 2004)
"Captopril was given orally at a dose of 50 mg bd daily."2.71Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. ( Balkwill, F; Blann, AD; Caine, GJ; Christodoulos, K; Dobbs, N; Ganesan, TS; Gompertz, N; Harris, AL; Jones, PH; Kakkar, AJ; Kumar, S; Talbot, DC; Thavasu, P, 2004)
"Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition."2.70Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. ( Breddin, HK; Hach-Wunderle, V; Kakkar, VV; Nakov, R, 2001)
" According to our experience, Fragmin at the dosage used proved to be both effective and safe in these patients."2.68Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin). ( Abad, A; Alastrue, A; Mira, X; Monreal, M; Muxart, J; Rosell, R; Rull, M, 1996)
"En cas de MTEV liée au cancer, les héparines de bas poids moléculaire (HBPM) et en particulier la daltéparine, ont longtemps ­représenté le traitement de référence."2.61[Direct oral anticoagulants in the treatment of cancer-associated thrombosis]. ( Marti, C; Righini, M; Robert-Ebadi, H; Rossel, A; Stebler-Fontaine, L, 2019)
"Rivaroxaban is a potential option for patients with cancer and VTE."2.58Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis. ( Chen, D; Xing, J; Yin, X, 2018)
"Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE."2.58Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. ( Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE, 2018)
"Patients with cancer are at increased risk of recurrent venous thromboembolism (VTE) and bleeding."2.58Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. ( Bauersachs, R; Martínez-Zapata, MJ; Mathioudakis, AG; Mousa, SA, 2018)
"For patients with active cancer (N = 759), the analysis on the efficacy outcomes demonstrated a trend in favour of NOAC (OR 0."2.50Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. ( Larsen, TB; Lip, GY; Nielsen, PB; Rasmussen, LH; Skjøth, F, 2014)
"Compared with patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE."2.50Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Kahale, L; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I, 2014)
"No major bleeding was observed in the patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin."2.50Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. ( Di Nisio, M; Otten, HM; Porreca, E; Rutjes, AW, 2014)
" However, very few studies compare different dosing regimens of the LMWH itself."2.48Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary. ( Diaz, AH; Gilreath, JA; Rodgers, GM, 2012)
"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."2.47Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)
"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."2.47Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)
"Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)."2.47Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. ( Akl, EA; Barba, M; Gunukula, S; Muti, P; Schünemann, H; Sperati, F; Terrenato, I; Vasireddi, SR, 2011)
"An association between cancer and thrombosis has been recognized since 1865."2.46Bemiparin in oncology. ( Lecumberri Villamediana, R; Monreal Bosch, M; Prandoni, P; Vignoli, A, 2010)
"Cancer is a major risk factor for the development of venous thromboembolism (VTE)."2.44Management of venous thromboembolism in patients with cancer: role of dalteparin. ( Linkins, LA, 2008)
"Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of approximately 5,000."2.42Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. ( Hull, RD; Pineo, GF, 2004)
"This single-center study suggests that DOACs are both safe and efficacious for the treatment of VTE in children with cancer."1.91Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. ( Branchford, B; Liegl, M; Malec, L; Scheuermann, A; Simpson, P, 2023)
"Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thrombosis (CAT) are scarce."1.72Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. ( Cajfinger, F; Crichi, B; Farge, D; Frere, C; Janus, N; Le Maignan, C; Marjanovic, Z; Rueda-Camino, JA; Spiess, N, 2022)
" Enoxaparin is traditionally dosed using weight."1.62Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy. ( Andrick, B; Graham, J; Grassi, S; Hart, K; Manikowski, J, 2021)
"Common VTE risk factors included cancer (46."1.62Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study. ( Johnson, SA; Jones, AE; Lai, N; Witt, DM, 2021)
"Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited."1.56Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. ( Antonio, M; Domènech, P; Peñafiel, J; Peris, J; Pina, E; Rosselló, E; Tebe, C, 2020)
"Hospitalized cancer patients are at increased risk of thrombosis and prophylaxis with heparin is recommended."1.56Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin. ( Ackerman, S; Haim, N; Keren-Politansky, A; Litvak, M; Maurice-Dror, C; Nadir, Y, 2020)
" Given the favourable safety profile of NOACs (especially if a reduced dosage of Apixaban or Rivaroxaban is initiated after at least six months of therapeutic anticoagulation), extended oral anticoagulation of indefinite duration should be considered for all patients with intermediate risk of recurrence."1.56[Antithrombotic Treatment of Pulmonary Embolism]. ( Ebner, M; Lankeit, M, 2020)
"Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome."1.51Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. ( Connell, NT; Connors, JM, 2019)
"The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%)."1.48Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. ( Alzghari, SK; Baty, KA; Evans, MF; Garza, JE; Hashimie, YF; Herrington, JD; Seago, SE; Shaver, C, 2018)
"Adults with active cancer and an acute VTE were included."1.48Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. ( Anselmo, L; Borrego, ME; Burnett, A; Fuller, K; Jakeman, B; Malecki, S, 2018)
"Cancer is a known hypercoagulable state that leads to an increased risk of venous thromboembolism (VTE)."1.48Anticoagulation prescribing patterns in patients with cancer. ( Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E, 2018)
"A personal history of malignancy and type 2 diabetes increase the risk of PMVT."1.48Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. ( Blanco, DG; Boyce, SG; De La Cruz-Munoz, N; Domkowski, P; Funes, DR; Ghanem, M; Jawad, MA; Menzo, EL; Moon, RC; Radecke, J; Rosenthal, R; Teixeira, AF; Young, MK, 2018)
"The incidence of venous thromboembolism has increased in patients following cancer surgery despite the increased use of prophylactic anticoagulants, suggesting standard doses may be inadequate."1.48Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery. ( Baumgartner, JM; Block, S; Costantini, TW; Lowy, AM; McKenzie, S, 2018)
"In the Hokusai VTE Cancer study, 1050 patients with cancer and acute VTE were randomized to oral edoxaban or subcutaneous dalteparin for at least 6 months and up to 12 months."1.48[Treatment of cancer-associated venous thromboembolism]. ( Di Nisio, M, 2018)
"In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL."1.46Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. ( Mantha, S; Miao, Y; Parameswaran, R; Soff, GA; Wills, J, 2017)
"5 mg/kg SC once daily are both FDA-approved dosing regimens for the treatment of pulmonary embolism (PE)."1.43Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients. ( Chisholm, G; King, AC; Ma, MQ; Toale, KM, 2016)
"To assess the risk for intracranial hemorrhage associated with the administration of therapeutic doses of low-molecular-weight heparin, we performed a matched, retrospective cohort study of 293 patients with cancer with brain metastases (104 with therapeutic enoxaparin and 189 controls)."1.42Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. ( Campigotto, F; Coletti, E; Donato, J; Neuberg, D; Uhlmann, EJ; Weber, GM; Zwicker, JI, 2015)
" These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer."1.42Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. ( Ashrani, A; Bockenstedt, PL; Chesney, C; Eby, C; Engh, AM; Fanikos, J; Fenninger, RB; Fogerty, AE; Gao, S; Goldhaber, SZ; Hendrie, P; Holmstrom, B; Kuderer, N; Lee, A; Lee, JT; Lovrincevic, M; McMillian, N; Millenson, MM; Neff, AT; Ortel, TL; Paschal, R; Shattil, S; Siddiqi, T; Smock, KJ; Soff, G; Streiff, MB; Wang, TF; Yee, GC; Zakarija, A, 2015)
"Among patients with cancer-related VTE, 59."1.38Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012)
"Venous thromboembolism is a common and potentially fatal complication in patients with advanced cancer."1.36Thromboprophylaxis during chemotherapy in patients with advanced cancer. ( Agnelli, G; Verso, M, 2010)
"Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated."1.36Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010)
"Underuse of deep vein thrombosis (DVT) prophylaxis persists, despite guidelines supporting its use in hospitalized cancer patients."1.35Use of deep vein thrombosis prophylaxis in hospitalized cancer patients. ( Awar, Z; Sheikh-Taha, M, 2009)
"Venous thromboembolism is a common and life-threatening complication in patients with advanced cancer."1.34Thromboprophylaxis during chemotherapy after advanced cancer. ( Agnelli, G; Verso, M, 2007)
"Many cancer patients are still poorly assessed for risk of VTE."1.34Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. ( Altimiras, J; Balibrea, JL; Gómez-Outes, A; Larruzea, I; Martínez-González, J; Rocha, E, 2007)
"The results between cancer-activated and tissue factor-activated blood were similar."1.34Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. ( Cloonan, ME; DiNapoli, M; Mousa, SA, 2007)
"In patients with malignant tumors not only the incidence of VTE is higher but the course of VTE is more severe and relapses are more frequent."1.33[Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study]. ( Farkas, E; Köves, I; Mátrai, Z; Péley, G; Rényi-Vámos, F, 2005)
"We investigated the incidence of venous thrombosis in patients hospitalised from 1992 to 1996 and related our findings to literature reports."1.31Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense? ( den Heijer, M; Nijs, AM; Schuurman, B, 2000)
"Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality."1.30Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999)

Research

Studies (177)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (2.26)18.2507
2000's51 (28.81)29.6817
2010's85 (48.02)24.3611
2020's37 (20.90)2.80

Authors

AuthorsStudies
Barni, S5
Bonizzoni, E3
Verso, M12
Gussoni, G6
Petrelli, F2
Perrone, T2
Agnelli, G17
Somonova, OV2
Madzhuga, AV2
Elizarova, AL2
Zubrikhina, GN2
Klerk, CP4
Niers, TM1
Brüggemann, LW1
Smorenburg, SM3
Richel, DJ3
Spek, CA1
Van Noorden, CJ1
Bianchini, C2
Mandalà, M3
Cavanna, L1
Labianca, R3
Buzzi, F1
Scambia, G1
Passalacqua, R1
Ricci, S1
Gasparini, G3
Lorusso, V2
Tonato, M1
van Doormaal, FF2
Di Nisio, M10
Otten, HM3
Prins, M3
Buller, HR10
Brighenti, M1
Khorana, AA10
Mismetti, P5
Mille, D1
Laporte, S5
Charlet, V1
Buchmüller-Cordier, A1
Jacquin, JP1
Fournel, P1
Dutrey-Dupagne, C1
Decousus, H4
Lensing, AW3
Prins, MH2
Piovella, F2
Prandoni, P3
Bos, MM1
van Tienhoven, G1
Meijers, JC1
Weber, C1
Merminod, T1
Herrmann, FR1
Zulian, GB1
Lisets'kyĭ, VA1
Lukashevych, AB1
Oliĭnychenko, HP1
Kliusov, OM1
Iatsenko, SM1
Galeano-Valle, F1
Pérez-Rus, G1
Demelo-Rodríguez, P1
Ordieres-Ortega, L1
Ortega-Morán, L1
Muñoz-Martín, AJ1
Medina-Molina, S1
Alvarez-Sala-Walther, LA1
Del-Toro-Cervera, J1
Doello, K1
Amezcua, V1
Pina, E1
Antonio, M1
Peris, J1
Rosselló, E1
Domènech, P1
Peñafiel, J1
Tebe, C1
Calderero Aragón, V1
de Gregorio Ariza, MA1
Pazo Cid, R1
Puértolas Hernández, T1
Lostalé Latorre, F1
Artal Cortés, A1
Antón Torres, A1
Kakkar, VV2
Balibrea, JL2
Martínez-González, J2
Monreal Bosch, M1
Vignoli, A1
Lecumberri Villamediana, R1
Altimiras, J1
Larruzea, I1
Gómez-Outes, A1
Rocha, E1
Sarangi, SN1
Gaballah, M1
Nolfi-Donegan, D1
Battaglia, M1
Amin, S1
Amodio, J1
Acharya, SS1
Baumann Kreuziger, L1
Feng, M1
Bartosic, A1
Simpson, P2
Wang, TF6
Stitzel, HJ1
Hue, JJ1
Elshami, M1
McCaulley, L1
Hoehn, RS1
Rothermel, LD1
Ammori, JB1
Hardacre, JM1
Winter, JM1
Ocuin, LM1
Scheuermann, A1
Liegl, M1
Branchford, B1
Malec, L1
Gulati, S1
Eckman, MH1
Guan, Z1
Wang, R1
Hussain, RH1
Fredenburgh, JC1
Jaffer, IH1
Weitz, JI5
Alsehly, AA1
Carrier, M8
Maurice-Dror, C1
Litvak, M1
Keren-Politansky, A1
Ackerman, S1
Haim, N1
Nadir, Y1
Zwicker, JI5
Roopkumar, J1
Puligandla, M1
Schlechter, BL1
Sharda, AV1
Peereboom, D1
Joyce, R1
Bockorny, B1
Neuberg, D3
Bauer, KA2
Diver, E1
Mokadem, ME1
Hassan, A1
Algaby, AZ1
Hart, K1
Andrick, B1
Grassi, S1
Manikowski, J1
Graham, J1
Lai, N1
Jones, AE1
Johnson, SA1
Witt, DM1
Elias, A2
Morgenstern, Y1
Braun, E1
Brenner, B6
Tzoran, I1
Alzghari, SK1
Seago, SE1
Garza, JE1
Hashimie, YF1
Baty, KA1
Evans, MF1
Shaver, C1
Herrington, JD1
Nam, KW1
Kim, CK1
Kim, TJ1
An, SJ1
Oh, K1
Ko, SB1
Yoon, BW1
Fuller, K1
Malecki, S1
Anselmo, L1
Borrego, ME1
Jakeman, B1
Burnett, A1
Xiang, E1
Ahuja, T1
Raco, V1
Cirrone, F1
Green, D2
Papadopoulos, J1
Moon, RC1
Ghanem, M1
Teixeira, AF1
De La Cruz-Munoz, N1
Young, MK1
Domkowski, P1
Radecke, J1
Boyce, SG1
Rosenthal, R1
Menzo, EL1
Blanco, DG1
Funes, DR1
Jawad, MA1
Baumgartner, JM1
McKenzie, S1
Block, S1
Costantini, TW1
Lowy, AM1
Nicklaus, MD1
Ludwig, SL1
Kettle, JK1
Navi, BB1
Marshall, RS1
Bobrow, D1
Singer, S1
Stone, JB1
DeSancho, MT1
DeAngelis, LM1
Xing, J1
Yin, X1
Chen, D1
Stepien, K1
Nowak, K1
Zalewski, J1
Pac, A1
Undas, A1
Wysokinski, WE3
Houghton, DE1
Casanegra, AI1
Vlazny, DT1
Bott-Kitslaar, DM1
Froehling, DA1
Hodge, DO1
Peterson, LG1
Mcbane, RD2
Changolkar, A1
Menditto, L1
Shah, M1
Puto, K1
Farrelly, E1
Nasser, NJ1
Na'amad, M1
Weinberg, I1
Gabizon, AA1
Larsen, TB1
Nielsen, PB1
Skjøth, F1
Rasmussen, LH1
Lip, GY2
King, AC1
Ma, MQ1
Chisholm, G1
Toale, KM1
Azık, F1
Gökçebay, DG1
Tavil, B1
Işık, P1
Tunç, B1
Uçkan, D1
Donato, J1
Campigotto, F2
Uhlmann, EJ1
Coletti, E1
Weber, GM1
Kreuziger, LB1
Kooistra, HA1
Gebel, M1
Sahin, K1
Meijer, K1
Streiff, MB1
Holmstrom, B1
Ashrani, A2
Bockenstedt, PL1
Chesney, C1
Eby, C1
Fanikos, J2
Fenninger, RB1
Fogerty, AE1
Gao, S1
Goldhaber, SZ4
Hendrie, P1
Kuderer, N1
Lee, A1
Lee, JT1
Lovrincevic, M1
Millenson, MM1
Neff, AT1
Ortel, TL3
Paschal, R1
Shattil, S1
Siddiqi, T1
Smock, KJ1
Soff, G2
Yee, GC1
Zakarija, A1
McMillian, N1
Engh, AM1
Cohen, A4
Gallus, AS1
Lee, TC1
Pak, R1
Raskob, GE5
Yamabe, T1
Ageno, W4
Rutjes, AW2
Pap, AF1
Pignataro, BS1
Nishinari, K1
Cavalcante, RN1
Centofanti, G1
Yazbek, G1
Krutman, M1
Bomfim, GAZ1
Fonseca, IYI1
Teivelis, MP1
Wolosker, N1
Sanches, SM1
Ramacciotti, E1
Mantha, S2
Miao, Y1
Wills, J1
Parameswaran, R1
Soff, GA1
Davidson, BL1
Gallus, A1
Reeves, D1
Liu, CY1
Awar, Z1
Sheikh-Taha, M1
Traby, L1
Kaider, A1
Schmid, R1
Kranz, A1
Quehenberger, P1
Kyrle, PA1
Eichinger, S1
Samama, CM1
Godier, A1
Piazza, G2
Diaz, AH1
Rodgers, GM1
Gilreath, JA1
Rao, A1
Seger, AC1
Catapane, E1
Chen, X1
Kahn, SR2
Springmann, V1
Schulman, S1
Martineau, J1
Stewart, JA1
Komari, N1
McLeod, A1
Strulovitch, C1
Blostein, M1
Faucher, JP1
Gamble, G1
Gordon, W1
Kagoma, PK1
Miron, MJ1
Laverdière, D1
Game, M1
Mills, A1
Liebman, HA1
Caughey, T1
Rosovsky, R1
Kessler, CM3
Eneman, J1
Raghavan, V1
Lenz, HJ1
Bullock, A1
Buchbinder, E1
Furie, B1
Bergqvist, D3
Alikhan, R2
Cohen, AT4
Combe, S1
Samama, MM1
Desjardins, L1
Eldor, A1
Janbon, C1
Leizorovicz, A1
Olsson, CG1
Turpie, AG3
Bertoglio, S2
Di Somma, FC1
Paoletti, F2
Bazzan, M2
Parise, P1
Quintavalla, R1
Naglieri, E1
Santoro, A1
Imberti, D2
Sorarù, M1
Mosca, S2
Ibrahim, RB1
Peres, E1
Dansey, R1
Abidi, MH1
Abella, EM1
Gumma, MM1
Milan, N1
Smith, DW1
Heilbrun, LK1
Klein, J1
Farkas, E1
Péley, G1
Mátrai, Z1
Rényi-Vámos, F1
Köves, I1
Deitcher, SR1
Merli, G1
Rigas, JR1
Lyons, RM1
Fareed, J1
Sel'chuk, VIu1
Bokhian, AIu1
Stine, KC1
Saylors, RL1
Saccente, CS1
Becton, DL1
Cloonan, ME1
DiNapoli, M1
Mousa, SA2
Kamphuisen, PW7
Lazzaro, A1
Paciaroni, M1
Walsh-McMonagle, D1
Schuurman, B1
den Heijer, M1
Nijs, AM1
Breddin, HK1
Hach-Wunderle, V1
Nakov, R1
Haas, S2
Schellong, SM1
Tebbe, U1
Gerlach, HE1
Bauersachs, R13
Melzer, N1
Abletshauser, C1
Sieder, C1
Bramlage, P1
Riess, H1
Kakkar, AK8
Wolf, H1
Encke, A1
Muñoz, A5
Franco, L1
Mahé, I2
Connors, JM7
Hamulyak, EN1
Lambert, C3
Suero, MR1
Torbicki, A3
Becattini, C7
Planquette, B1
Bertoletti, L3
Charles-Nelson, A1
Grange, C1
Pernod, G1
Couturaud, F2
Falvo, N3
Sevestre, MA1
Ray, V1
Burnod, A2
Brebion, N1
Roy, PM1
Timar-David, M1
Aquilanti, S1
Constans, J1
Bura-Rivière, A1
Brisot, D1
Chatellier, G1
Sanchez, O3
Meyer, G13
Girard, P2
Huisman, M2
Hartman, LR1
Nurmeev, I1
Svirin, P1
Wolter, KD1
Yan, JL1
Jani, D1
Goldenberg, NA1
Sherman, N1
Raithel, M1
Haibach, M1
Kremenevski, I1
Arnold, E1
Ringwald, J1
Arce-Huamani, MA1
Barboza, JJ1
Martínez-Herrera, JF1
Torres-Roman, JS1
Maguiña, JL1
Stebler-Fontaine, L1
Rossel, A1
Marti, C1
Righini, M1
Robert-Ebadi, H1
Huisman, MV4
Sueiro, MR1
Campanini, M2
Fontanella, A2
Vescovo, G3
Ebner, M1
Lankeit, M1
Miranda, S1
Levesque, H1
Riaz, IB2
Marshall, AL2
Badgett, RG2
de Jong, LA1
van der Velden, AWG1
Hulst, MV1
Postma, MJ1
Chen, L1
Chen, Q1
Zhu, M1
Zhuang, Z1
Fuentes, HE1
Naqvi, SAA1
He, H1
Sipra, QR1
Tafur, AJ1
Padranos, L1
Vandvik, PO1
Montori, V1
Bryce, AH1
Liu, H1
Murad, MH1
Giustozzi, M1
Ruperez Blanco, AB1
Szmit, S1
Dentali, F1
Maraziti, G1
Manfellotto, D1
Sanchez, A1
McBane Ii, R1
Loprinzi, CL2
Perez-Botero, J1
Leon Ferre, RA1
Henkin, S1
Lenz, CJ1
Le-Rademacher, JG1
van Es, N4
Verhamme, P3
Garcia, D4
Grosso, MA2
Kovacs, MJ6
Mercuri, MF3
Segers, A4
Shi, M1
Yeo, E1
Zhang, G2
Hakoum, MB1
Kahale, LA1
Tsolakian, IG1
Matar, CF1
Yosuico, VE1
Terrenato, I5
Sperati, F5
Barba, M5
Schünemann, H5
Akl, EA6
Young, AM1
Marshall, A1
Thirlwall, J1
Chapman, O1
Lokare, A1
Hill, C1
Hale, D1
Dunn, JA1
Lyman, GH3
Hutchinson, C1
MacCallum, P1
Kakkar, A2
Hobbs, FDR1
Petrou, S1
Dale, J1
Poole, CJ1
Maraveyas, A2
Levine, M1
Noble, S1
Lee, AYY5
O'Connell, C1
Kraaijpoel, N1
Mulder, FI1
Beyer-Westendorf, J2
Grosso, M1
Middeldorp, S1
Hernandez, CR1
Santamaria, A1
Schwocho, L2
Abreu de Sousa, J1
Hutchinson, A1
Rees, S1
Young, A1
Date, K1
Johnson, MJ1
Woodruff, S3
Feugère, G2
Abreu, P2
Heissler, J2
Li, A1
Manohar, PM1
Garcia, DA1
Steuten, LM1
Connell, NT1
Weitz, J1
Buller, H1
Raskob, G2
Miyazaki, Y1
Sase, K1
Hasegawa, K1
Morimoto, T1
Kahale, L1
Neumann, I1
Muti, P4
Babilonia, KM1
Golightly, LK1
Gutman, JA1
Hassell, KL1
Kaiser, JN1
Kiser, TH1
Klem, PM1
Trujillo, TC1
Francis, CW2
Monreal, M4
Spyropoulos, AC1
Pabinger, I2
Bleker, SM1
Boda, Z1
Chlumsky, J1
Gibbs, H1
Ockelford, P1
Ruiz, MT1
Jen, F1
Kuderer, NM1
Wun, T1
Rubens, D1
Hobbs, S1
Iyer, R1
Peterson, D1
Baran, A1
Kaproth-Joslin, K1
Dranitsaris, G2
Shane, LG1
Galanaud, JP1
Stemer, G1
Debourdeau, P2
Linkins, LA1
De Cicco, M1
Matovic, M1
Balestreri, L1
Steffan, A1
Pacenzia, R1
Malafronte, M1
Fantin, D1
Bertuzzi, CA1
Fabiani, F1
Morassut, S1
Bidoli, E1
Veronesi, A1
Vasireddi, SR3
Gunukula, S3
Bick, RL2
Lee, AY5
Levine, MN4
Baker, RI2
Bowden, C2
Rickles, FR2
Julian, JA2
Haley, S1
Gent, M2
Lersch, C1
Kotowa, W1
Fung, S1
Janssen, D1
Hiller, E1
Kadziola, Z1
Lemoine, NR1
Low, V1
Patel, HK1
Rustin, G1
Thomas, M1
Quigley, M1
Williamson, RC1
Jones, PH1
Christodoulos, K2
Dobbs, N1
Thavasu, P1
Balkwill, F1
Blann, AD2
Caine, GJ2
Kumar, S1
Kakkar, AJ1
Gompertz, N1
Talbot, DC1
Ganesan, TS1
Harris, AL2
Pineo, GF2
Hull, RD2
Zacharski, L1
Jiménez, JA1
Roncales, J1
Vilaseca, B1
Keeney, M1
Mackinnon, KM1
Karthaus, M1
Kretzschmar, A1
Kröning, H1
Biakhov, M1
Irwin, D1
Marschner, N1
Slabber, C1
Fountzilas, G1
Garin, A1
Abecasis, NG1
Baronius, W1
Steger, GG1
Südhoff, T1
Giorgetti, C1
Reichardt, P1
Burton, A1
Vincent, M1
Crowther, M1
Sideras, K1
Schaefer, PL1
Okuno, SH1
Sloan, JA1
Kutteh, L1
Fitch, TR1
Dakhil, SR1
Levitt, R1
Alberts, SR1
Morton, RF1
Rowland, KM1
Novotny, PJ1
Rodger, M1
Anderson, DR1
Andreou, R1
Mangel, JE1
Morrow, B2
Clement, AM1
Wells, PS2
Alastrue, A1
Rull, M1
Mira, X1
Muxart, J1
Rosell, R1
Abad, A1
Savage, KJ1
Schulz, V1
Goudie, D1
Cruickshank, M1
Xynogalos, S1
Simeonidis, D1
Papageorgiou, G1
Pouliakis, A1
Charalambakis, N1
Lianos, E1
Mazlimoglou, E1
Liatsos, AN1
Kosmas, C1
Ziras, N1
Frere, C1
Crichi, B1
Rueda-Camino, JA1
Cajfinger, F1
Spiess, N1
Janus, N1
Le Maignan, C1
Marjanovic, Z1
Farge, D1
Fioretti, AM1
Leopizzi, T1
Puzzovivo, A1
Giotta, F1
Luzzi, G1
Oliva, S1
Chapelle, C1
Falchero, L1
Cloarec, N1
Monnet, I1
Tomasini, P1
Boulon, C1
Boutruche, B1
Scotté, F1
Lamblin, A1
Jara-Palomares, L1
Solier-Lopez, A1
Elias-Hernandez, T1
Asensio-Cruz, M1
Blasco-Esquivias, I1
Marin-Barrera, L1
de la Borbolla-Artacho, MR1
Praena-Fernandez, JM1
Montero-Romero, E1
Navarro-Herrero, S1
Serrano-Gotarredona, MP1
Sánchez-Díaz, JM1
Palacios, C1
Otero, R1
Dimakakos, EP1
Vathiotis, I1
Syrigos, K1
Janas, MS5
Jarner, MF5
Falanga, A1
Labianca, RF1
Mantovani, L1
Noel-Savina, E1
Descourt, R1
André, M1
Leroyer, C1
Martínez-Zapata, MJ1
Mathioudakis, AG1
Romera, A2
Cairols, MA1
Vila-Coll, R1
Martí, X1
Colomé, E1
Bonell, A1
Lapiedra, O1
Pérez de Llano, LA1
Hainer, JW1
Sprogel, P1
Lindenstroem, E1
Brant, RF1
Mah, AF1
Burke, N1
Dear, R1
Wong, T1
Cook, R1
Solymoss, S1
Poon, MC1
Heller, S1
Krause, M1
Porreca, E1
Chen, YW1
George, DJ1
Fisher, W1
Lassen, MR1
Mouret, P1
Chaudhari, U1
Lawson, F1
Schünemann, HJ1
Gras, J1

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium). A Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study.[NCT00951574]Phase 31,166 participants (Actual)Interventional2003-10-31Completed
A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate[NCT00312013]Phase 3503 participants (Actual)Interventional2006-05-31Completed
Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer[NCT03646409]542 participants (Actual)Observational2018-06-11Completed
Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958]150 participants (Actual)Observational2014-01-31Completed
A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients[NCT02706249]Phase 250 participants (Actual)Interventional2016-04-30Completed
Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003]Phase 3100 participants (Anticipated)Interventional2019-07-03Recruiting
Pharmacokinetics of Low Molecular Weight Heparin in Cancer Patients Compared to Patients With Unstable Angina Pectoris; The Possible Role of Heparanase[NCT00716898]25 participants (Actual)Observational2009-02-28Completed
Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445]700 participants (Anticipated)Observational2012-07-31Completed
A Randomized Controlled Trial of Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles[NCT00908960]Phase 270 participants (Actual)Interventional2009-05-31Completed
An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764]Phase 3200 participants (Anticipated)Interventional2020-05-08Recruiting
A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412]Phase 33,254 participants (Actual)Interventional2007-01-31Completed
Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.[NCT02746185]Phase 3159 participants (Actual)Interventional2016-09-30Completed
A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES[NCT00952380]Phase 238 participants (Actual)Interventional2009-08-31Completed
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406]Phase 31,168 participants (Actual)Interventional2017-04-13Active, not recruiting
CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study[NCT02583191]Phase 3246 participants (Actual)Interventional2016-03-23Terminated (stopped due to Recruitment was not as expected.)
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)[NCT02744092]811 participants (Actual)Interventional2016-12-13Completed
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancrea[NCT03139487]Phase 2176 participants (Anticipated)Interventional2017-08-07Recruiting
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism[NCT02585713]Phase 3300 participants (Actual)Interventional2015-11-20Completed
Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855]240 participants (Anticipated)Observational2020-08-01Recruiting
A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682]Phase 31,046 participants (Actual)Interventional2015-07-16Completed
A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients[NCT00876915]Phase 3218 participants (Actual)Interventional2009-07-31Terminated (stopped due to slow enrollment and lack of continuing funds)
Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354]Phase 3740 participants (Actual)Interventional2008-07-31Completed
Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051]370 participants (Actual)Observational2011-08-31Active, not recruiting
Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046]Phase 356 participants (Actual)Interventional2010-08-31Terminated (stopped due to Due to slow inclusion of patients)
Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432]0 participants (Actual)Observational2012-11-30Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project)
Comparison of Effectiveness and Safety of Two Methods for Installing Femoral Central Venous Catheters in Pediatric Intensive Care Units : Anatomical Method vs Ultrasound in Real Time.[NCT02318940]99 participants (Actual)Interventional2014-12-31Completed
A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)[NCT01708850]Phase 470 participants (Actual)Interventional2012-11-30Completed
A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity[NCT00216866]Phase 270 participants Interventional2002-09-30Completed
Metaxa's Thromboprophylaxis Program in Oncological & Surgical Patients[NCT04248348]600 participants (Anticipated)Observational2018-12-01Recruiting
Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025]Phase 3900 participants (Actual)Interventional2010-08-31Completed
EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial[NCT01853202]40 participants (Actual)Interventional2013-03-31Completed
Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study[NCT02025894]3,032 participants (Actual)Observational2010-06-30Completed
A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy[NCT00694382]Phase 33,212 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Symptomatic Venous Thromboembolic Events (VTE)

Comparing number of symptomatic VTE (data collected prior to unblinding) for the standard dose (Arm A) versus intermediate dose enoxaparin (Arm B). (NCT02706249)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
A: Standard Dose Enoxaparin0
B: Weight Adjusted Enoxaparin0

Number Participants With Major Hemorrhage

Number of major hemorrhage in weight-adjusted enoxaparin arm and standard-dose enoxaparin arm (NCT02706249)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
A: Standard Dose Enoxaparin1
B: Weight Adjusted Enoxaparin0

Total Number of Venous Thromboembolic Events (VTE) in Standard Dose Enoxaparin Arm at 17 Days

To investigate the numbers of VTE in hospitalized cancer patients receiving standard dose (NCT02706249)
Timeframe: 17 days only measured in Arm A (Standard dose enoxaparin)

Interventionparticipants (Number)
A: Standard Dose Enoxaparin2

2-Month Cumulative Incidence of VTE

2-month cumulative incidence of venous thromboembolism (VTE) is the probability of experiencing within 2 months of study entry the following events: any symptomatic proximal or distal lower extremity deep vein thrombosis, symptomatic pulmonary embolism or fatal pulmonary embolism diagnosed by autopsy, or asymptomatic proximal deep vein thrombosis diagnosed by screening compression ultrasound. (NCT00908960)
Timeframe: Assessment with lower extremity ultrasound occured at day 60/ month 2

Interventionpercent probability (Number)
High TFMP: Enoxaparin5.6
High TFMP: Observation27.2
Low TFMP: Observation7.2

Incidence of Major Hemorrhage Events

Incidence is the number of patients experiencing at least one major hemorrhage events as defined according to International Society on Thrombosis and Haemostasis (ISTH) guidelines. (Schulman and Kearon 2005) (NCT00908960)
Timeframe: Assessed during the 60 day therapy

InterventionParticipants (Count of Participants)
High TFMP: Enoxaparin0
High TFMP: Observation0
Low TFMP: Observation0

Overall Survival

Overall survival is defined as the time from study entry to death or date last known alive and estimated using Kaplan-Meier (KM) methods. (NCT00908960)
Timeframe: Assessed up to approximately 30 months

Interventionmonths (Median)
High TFMP: Enoxaparin17.8
High TFMP: Observation11.8
Low TFMP: Observation17.3

Maintenance Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Levels

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data for day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

InterventionIU/kg (Mean)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)207.50
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)141.85
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)132.40
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)115.06

Median Dose of Dalteparin Required to Achieve Prespecified Therapeutic Anti- Factor Xa Level

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 international unit per milliliter (IU/mL). Cumulative data of Day 1 to 7 has been reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

InterventionIU/mL (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)125

Number of Dose Adjustments Required to Achieve Prespecified Therapeutic Anti-Xa Levels

During dose adjustment phase, doses were adjusted according to prespecified therapeutic anti-Xa levels in order to achieve target prespecified therapeutic anti-factor Xa levels (0.5 to 1.0 IU/mL). Number of dose adjustments which were done within the specified time window of up to 4 hours post dose on all days (1 to 7) to achieve the prespecified therapeutic anti-Xa levels are reported. (NCT00952380)
Timeframe: 4 hours post-dose at each Day 1 to 7 in dose adjustment phase

Interventiondose adjustment (Median)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)3.5
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)0.5
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)0.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)0.0

Number of Participants With Laboratory Abnormalities

Criteria:hematology:hemoglobin, hematocrit, erythrocytes less than(<)0.8*lower limit of normal(LLN), platelets <0.5*LLN >1.75*upper limit of normal (ULN),leukocytes <0.6* LLN >1.5* ULN, lymphocytes, lymphocytes/Leukocytes, neutrophils, neutrophils/leukocytes <0.8* LLN >1.2* ULN, basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes monocytes monocytes/leukocytes >1.2*ULN, activated partial thromboplastin time, prothrombin time, prothrombin international normalized ratio >1.1* ULN. Clinical chemistry: bilirubin >1.5*ULN, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase >3.0*ULN, protein, albumin <0.8* LLN >1.2* ULN, blood urea nitrogen, creatinine >1.3* ULN, sodium <0.95*LLN >1.05*ULN, potassium, chloride, calcium, magnesium <0.9* LLN >1.1* ULN, phosphate <0.8* LLN >1.2* ULN, glucose <0.6*LLN >1.5*ULN, estimated(est) creatinine clearance, est GFR modified and bedside schwartz, >1.0* ULN. Urinalysis: creatinine >1.0*ULN. (NCT00952380)
Timeframe: Baseline up to 104 days

InterventionParticipants (Count of Participants)
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)1
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)2
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)8
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)5
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)19

Number of Participants With New or Progressive Symptomatic Venous Thromboembolism (VTE)

Symptomatic VTE defined as new or progressive signs and symptoms as judged by the investigator including but not limited to: objective swelling, pain or tenderness, pitting edema, erythema or cyanosis. Progression of VTE: Progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

InterventionParticipants (Count of Participants)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)1
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)0

Percentage of Participants Who Achieved Prespecified Therapeutic Anti- Factor Xa Levels

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Percentage of participants who achieved the prespecified level during the dose adjustment phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase

Interventionpercentage of participants (Number)
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)0
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)100.0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)100.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)85.0

Time to Achieve Prespecified Therapeutic Anti- Factor Xa Levels

Time to achieve the target range (prespecified therapeutic anti- factor Xa levels) was defined as the number of days from the first dose of study drug to the final dose that achieves the target anti-factor Xa level. Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. Cumulative data of Day 1 to 7 is reported. (NCT00952380)
Timeframe: Day 1 to 7 in dose adjustment phase

Interventiondays (Median)
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)4.5
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)3.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)2.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)2.0

Time to First Occurrence of Major Bleeding Event

Time to first occurrence of major bleeding event was defined as the time interval (in days) between date of first study treatment and date of documentation of first major bleeding event. A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter, overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration, bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal or intraspinal). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

Interventiondays (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)NA

Time to First Occurrence of Symptomatic Recurrent Venous Thromboembolism (VTE)

It was defined as the time interval (in days) between date of first study treatment and date of documentation of first VTE. VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. If a DVT clot breaks off from a vein wall and flows towards the lungs and blocks some or all of the blood supply, it becomes PE. When a blood clot breaks, loose and travels in the blood, this is called VTE. VTE was confirmed by at least one radiographic test and was defined as any new or progressive VTE whose signs and symptoms (identified by the investigator) included: objective swelling or tenderness, pitting edema, erythema or cyanosis. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

Interventiondays (Median)
Dalteparin Sodium: All Participants (>= 0 to < 19 Years)NA

Absolute Values of Body Length of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeter (Median)
BaselineDay 2Day 30Day 60Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100104.7510010397.75

Absolute Values of Body Length of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,
Interventioncentimeter (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)545456606364
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)555555.3056.606061
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)172135135135135151.75

Absolute Values of Body Temperature of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventiondegree celsius (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)36.6036.7036.9036.5036.6036.70
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)36.7036.8536.4036.5036.7037.15
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)36.5036.8036.7036.6036.8036.75
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)37.0036.7036.7036.5036.6036.90
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)36.8036.8036.7036.7036.6036.80

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,
Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90PR: BaselinePR: Day 1PR: Day 2PR: Day 30PR: Day 60PR: Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)115.00112.00114.00120.50120.00107.0096.50121.00117.0088.0088.00114.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)70.0085.0075.0087.5094.5080.0073.0094.5093.00102.0095.0092.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)148.00146.00136.00138.00132.00122.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
PR: BaselinePR: Day 1PR: Day 2PR: Day 30PR: Day 60PR: Day 90
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)114.0087.0098.00101.0093.0096.00

Absolute Values of Heart Rate (HR) and Pulse Rate (PR) of Participants

Heart rate and pulse rate of participants were measured in terms of beats per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventionbeats per minute (bpm) (Median)
HR: BaselineHR: Day 1HR: Day 2HR: Day 30HR: Day 60HR: Day 90PR: Day 1PR: Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)146.00142.00130.00130.00184.00134.00108.00140.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeters (cm) (Median)
BaselineDay 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)55.0056.6060.0061.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

Interventioncentimeters (cm) (Median)
BaselineDay 1Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)54.0054.0060.0063.0064.00

Absolute Values of Height of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,
Interventioncentimeters (cm) (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)110.00115.80107.90115.10115.00109.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)133.00134.00142.00140.30139.70140.70
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)166.00166.00166.90167.75168.50166.65

Absolute Values of Respiratory Rate of Participants

Respiratory rate was defined as the number of breaths per minute. (NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionbreaths per minute (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)35.0034.0034.0034.0030.0024.00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)25.0036.0034.0036.0036.0034.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)24.0021.0020.0022.0020.0022.00
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)20.0018.0020.0022.0020.0020.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)20.0018.0018.0018.0020.0018.00

Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DSBP) in Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionmillimeters of mercury (mmHg) (Median)
SBP: BaselineSBP: Day 1SBP: Day 2SBP: Day 30SBP: Day 60SBP: Day 90DSBP: BaselineDSBP: Day 1DSBP: Day 2DSBP: Day 30DSBP: Day 60DSBP: Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)101.0097.0094.0077.074.0076.0060.0061.0048.0053.0051.0053.00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)50.00105.5075.0077.00102.00105.0041.0057.0053.0061.0057.0055.50
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)110.50112.0107.00112.00101.0097.5066.0065.5060.5064.0060.0060.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)96.00111.00112.00109.00118.00116.0067.0066.5070.0068.0067.0067.00
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)117.50113.00119.50118.00117.50116.0065.0064.0065.0069.0067.0069.00

Absolute Values of Weight of Participants

(NCT00952380)
Timeframe: Baseline, Day 1, Day 2, Day 30, Day 60, Day 90

,,,,
Interventionkilograms (Median)
BaselineDay 1Day 2Day 30Day 60Day 90
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)4.054.174.506.307.157.70
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)3.934.044.154.564.604.70
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)18.7817.2314.9515.5016.6021.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)36.6037.0039.3539.2038.3039.30
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)60.0063.4058.0063.8065.8059.60

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 5Eyes, ears, nose, throat: Visit 6Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Skin: ScreeningSkin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)001111223112434112000000101002100111100010001000000312223

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningGeneral appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)0000000000000000000000000000000000000000000000000000000000001110000

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)1010001000000000000000000000100000000100000000111000010000001001011001

Number of Participants With Physical Examination Abnormalities of Participants

Physical examinations included head, eyes, ears, nose, throat, neck, heart, chest, lungs, abdomen, extremities, skin, neurological status and general appearance. Abnormality in physical examination was based on investigator's discretion. Only those categories in which at least 1 participant had abnormality were reported. (NCT00952380)
Timeframe: Screening, Visit 2 (Baseline), Visit 3 (Day 1), Visit 4 (Day 2), Visit 5 (Day 30), Visit 6 (Day 60), Visit 7 (Day 90)

,
InterventionParticipants (Count of Participants)
Abdomen: ScreeningAbdomen: Visit 2Abdomen: Visit 3Abdomen: Visit 4Abdomen: Visit 5Abdomen: Visit 6Abdomen: Visit 7Chest: ScreeningChest: Visit 2Chest: Visit 3Chest: Visit 4Chest: Visit 5Chest: Visit 6Chest: Visit 7Extremities: ScreeningExtremities: Visit 2Extremities: Visit 3Extremities: Visit 4Extremities: Visit 5Extremities: Visit 6Extremities: Visit 7Eyes: ScreeningEyes: Visit 2Eyes: Visit 3Eyes: Visit 4Eyes: Visit 5Eyes: Visit 6Eyes: Visit 7Eyes, ears, nose, throat:ScreeningEyes, ears, nose, throat: Visit 3Eyes, ears, nose, throat: Visit 4Eyes, ears, nose, throat: Visit 5Eyes, ears, nose, throat: Visit 6Eyes, ears, nose, throat: Visit 7General appearance: ScreeningGeneral appearance: Visit 2General appearance: Visit 3General appearance: Visit 4General appearance: Visit 5General appearance: Visit 6General appearance: Visit 7Head: ScreeningHead: Visit 3Head: Visit 4Head: Visit 5Head: Visit 6Head: Visit 7Heart: ScreeningHeart: Visit 3Heart: Visit 4Heart: Visit 7Lungs: ScreeningLungs: Visit 4Lungs: Visit 6Lungs: Visit 7Neck: ScreeningNeck: Visit 4Neurological: ScreeningNeurological: Visit 2Neurological: Visit 3Neurological: Visit 4Neurological: Visit 5Neurological: Visit 7Nose: ScreeningNose: Visit 2Skin: ScreeningSkin: Visit 2Skin: Visit 3Skin: Visit 4Skin: Visit 5Skin: Visit 6Skin: Visit 7
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)221100012000000110000100000011002121100011111111010000010211000111012201
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)2023413200100310138322111211121231230122124254350012011121000110005136754

Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after the last dose of study drug (up to Day 132) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,,
InterventionParticipants (Count of Participants)
AEsSAEs
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)10
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)22
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)73
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)73
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)1913

Percentage of Participants Who Remained Within Prespecified Therapeutic Anti-Factor Xa Levels at Day 30, 60 and 90 in Follow up Phase

Prespecified therapeutic anti-factor Xa level was 0.5-1.0 IU/mL. The percentage of participants who had anti factor-Xa levels within the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow up phase

,,,
Interventionpercentage of participants (Number)
Day 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)100.0100.0100.0
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)100.0100.0100.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)33.375.050.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)93.381.872.7

Percentage of Participants With Anti-Factor Xa Levels Outside the Prespecified Range at Day 30, 60 and 90 in Follow up Phase

Prespecified therapeutic anti-factor Xa range was 0.5-1.0 IU/mL. The percentage of participants who had anti-factor Xa levels outside the prespecified therapeutic range at Day 30, 60 and 90 during the follow up phase were reported in this outcome measure. (NCT00952380)
Timeframe: Day 30, Day 60, Day 90 in follow-up phase

,,,
Interventionpercentage of participants (Number)
Day 30Day 60Day 90
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)000
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)000
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)66.725.050.0
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)6.718.227.3

Percentage of Participants With Clinical Response of Progression, Regression, Resolution and No Change in Venous Thromboembolism (VTE)

VTEs included both DVT and PE. DVT is a blood clot in the deep veins of the leg. PE is a blood clot in the lungs. Clinical response of progression was defined as progression of clot burden in terms of severity of occlusion, or involvement of new venous segments at any time after the initial diagnosis. Clinical response of regression: Regressed clot burden utilizing the same imaging modality as the screening visit. Clinical response of resolution: Thrombus resolution of the qualifying event measured by repeat imaging at the end of study (EOS) visit. (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,
Interventionpercentage of participants (Number)
ProgressionRegressionResolutionNo Change
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)00100.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)012.562.50
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)014.357.114.3
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)029.458.85.9

Percentage of Participants With Major and Minor Bleeding Event

A bleeding event was considered as major if it was clinically overt and satisfies 1 or more of the following criteria: fatal bleeding, bleeding accompanied by a decrease in hemoglobin of at least 2 grams per deciliter 24 hours, Overt bleeding deemed by the attending physician to necessitate permanent discontinuation of trial medication, Overt bleeding deemed by the attending physician to be unrelated to the participant's underlying condition and accompanied by blood product administration or bleeding occurred at a critical site (intraocular, intracranial, retroperitoneal). A bleeding event was considered as minor if it was clinically overt but not meeting the criteria for major or clinically relevant no major bleeding (bleeding resulting in any medical or surgical interventions but which did not meet the criteria for major bleeding). (NCT00952380)
Timeframe: Baseline up to 28 days after the last dose of study drug (up to Day 132)

,,,,
Interventionpercentage of participants (Number)
Major BleedingMinor Bleeding
Dalteparin Sodium: Group 1 (>=0 to <8 Weeks)00
Dalteparin Sodium: Group 2 (>=8 Weeks to <2 Years)50.00
Dalteparin Sodium: Group 3 (>=2 Years to <8 Years)050.0
Dalteparin Sodium: Group 4 (>=8 Years to <12 Years)057.1
Dalteparin Sodium: Group 5 (>=12 Years to <19 Years)040.0

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 3-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.2
Randomized Arm 2 (LMWH)10.7
Preference Cohort 1 (DOACs)10.3
Preference Cohort 2 (LMWH)10.5

Benefit of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the benefit of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The benefits scale has 3 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS benefits tool is then scored using the totals from each question with a total score from 3 to 15 possible. Higher scores signify greater satisfaction (greater benefits). (NCT02744092)
Timeframe: 6-months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)11.6
Randomized Arm 2 (LMWH)11.3
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)10.1

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 3 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.7
Randomized Arm 2 (LMWH)53.3
Preference Cohort 1 (DOACs)55.8
Preference Cohort 2 (LMWH)54.9

Burden of Anticoagulation Therapy Reported by Participants Via the Anti-Clot Treatment Scale (ACTS) Questionnaire

To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 6 months. The burden scale has12 items and patients are asked to rate their experiences on a 5-point scale of intensity (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The ACTS burden tool is then scored using the totals from each question with a total score from 12 to 60 possible. Higher scores signify greater satisfaction (lower burden). (NCT02744092)
Timeframe: 6 months

Interventionscore on a scale (Mean)
Randomized Arm 1 (DOACs)56.5
Randomized Arm 2 (LMWH)54.1
Preference Cohort 1 (DOACs)54.9
Preference Cohort 2 (LMWH)53.1

Cumulative Non-Fatal VTE Recurrence at 6 Months (%)

To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE. (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)6.1
Randomized Arm 2 (LMWH)8.8
Preference Cohort 1 (DOACs)7.5
Preference Cohort 2 (LMWH)4.1

Cumulative Rates of Major Bleeding

To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months. d. Major bleeding was defined as Grade >=3 on the Common Terminology Criteria for Adverse Events from the National Cancer Institute (NCI CTCAE) criteria version 5.0 (i.e., severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living). (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)5.2
Randomized Arm 2 (LMWH)5.6
Preference Cohort 1 (DOACs)11.5
Preference Cohort 2 (LMWH)7.6

Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 3-months

Change in mental health at 3 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 3-months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)-0.3
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)0.3
Preference Cohort 2 (LMWH)0.4

Health Related Quality of Life (Mental Health) Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire at 6-months

Change in mental health at 6 months from baseline. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The scores indicate change in score from baseline. (NCT02744092)
Timeframe: 6-months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)0.3
Randomized Arm 2 (LMWH)0.9
Preference Cohort 1 (DOACs)1.1
Preference Cohort 2 (LMWH)-1.9

Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire

Change in physical health at 3 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 3-month follow-up assessment. (NCT02744092)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)1.8
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)3.4
Preference Cohort 2 (LMWH)-0.3

Health Related Quality of Life Reported by Participants Via the Optum SF-12v2 Health Survey Questionnaire

Change in physical health at 6 months. Health-related quality of life was measured using the 12-Item Short Form Health Survey (SF-12) sub-scales for physical and mental health (score range, 0-100; higher scores indicate better physical and mental health functioning). Survey content included minor verbiage changes for clarity. The presented scores in this results section indicate the change (difference) in mean scores between the baseline and 6-month follow-up assessment. (NCT02744092)
Timeframe: 6 months

Interventionunits on a scale (Mean)
Randomized Arm 1 (DOACs)2.4
Randomized Arm 2 (LMWH)0.7
Preference Cohort 1 (DOACs)2.1
Preference Cohort 2 (LMWH)-2.8

Mortality Reported by Participants' Surrogates (Via Study-specific Questionnaire) or Clinicians (Via Study-specific Case Report Form)

To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months. Mortality was reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form) (NCT02744092)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Randomized Arm 1 (DOACs)21.5
Randomized Arm 2 (LMWH)18.4
Preference Cohort 1 (DOACs)16.3
Preference Cohort 2 (LMWH)23.8

6 Month Bleeding Rate

The rate (percentage) of patients experiencing major bleeding at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months

Interventionpercentage of patients (Number)
Arm A (Apixaban)0
Arm B (Dalteparin)2.1

Composite Bleeding Rate: Major Bleed or a Clinically Relevant Non-major Bleed

A similar analysis as described for the primary safety analysis will be used. The rate (percentage) of patients experiencing major bleeding or a clinically relevant non-major bleed at 6 months from treatment initiation and its associated 95% confidence interval was estimated separately by treatment arm using a cumulative incidence function, treating death without bleeding as a competing risk. (NCT02585713)
Timeframe: Up to 6 months

Interventionpercentage of patients (Number)
Arm A (Apixaban)7.0
Arm B (Dalteparin)8.1

Time to the First Event of the Composite Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE)

Analyzed using the same methods described above for the primary endpoint.Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE) is defined as the time from randomization to the date the patient experienced the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE). (NCT02585713)
Timeframe: Up to 3 months post-treatment

Interventionmonths (Median)
Arm A (Apixaban)NA
Arm B (Dalteparin)NA

Number of Participants With Adjudicated Major Bleeding Events While on Treatment

The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group32
Dalteparin Group16

Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group67
Dalteparin Group71

Number of Participants With Recurrent Deep Vein Thrombosis (DVT) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group19
Dalteparin Group35

Number of Participants With Recurrent Non-Fatal Pulmonary Embolism (PE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group21
Dalteparin Group24

Number of Participants With Recurrent Venous Thromboembolism (VTE) During the Overall Study Period

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group41
Dalteparin Group59

Number of Participants With Recurrent VTE, Major Bleed or All-Cause Death

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group235
Dalteparin Group228

Number of Participants With VTE-Related Death

(NCT02073682)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Edoxaban Group6
Dalteparin Group4

Percentage of Patients Who Experienced Clinically Significant Bleeding Events.

The percentage of patients who experienced a clinically significant bleeding event were recorded (including major and clinically significant non-major bleeding) over 13 weeks (12 weeks of study and an additional week of observation). Major bleeding was defined as being clinically overt and satisfying one of the following: decrease in hemoglobin of 2.0 g/dL, leading to transfusion of 2 or more units of blood or packed red cells, occurring in a critical site (intraocular, spinal/epidural, intracranial, retroperitoneal, or pericardial) or leading to death. Clinically significant non-major bleeding was defined as clinically overt, not meeting criteria for major bleeding and with one of the following characteristics: multiple-source, spontaneous hematoma > 25 cm², epistaxis > 5 mins, macroscopic hematuria not related to instrumentation, spontaneous rectal bleeding, gingival bleeding > 5 mins, hemoptysis, hematemesis or prolonged bleeding (> 5 minutes) after venipuncture. (NCT00876915)
Timeframe: 13 weeks

Interventionpercentage of participants (Number)
Dalteparin Injection14
No Therapy2

Percentage of Patients With Venous Thromboembolisms

The percentage of patients who developed a Venous thromboembolism were recorded within 12 weeks following randomization including all adjudicated occurrences of symptomatic DVT, PE and upper extremity thrombus as well as all asymptomatic DVT and PE detected by lower extremity ultrasonography and chest CT. (NCT00876915)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Dalteparin Injection12
No Therapy21

The Value of D-Dimer at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of D-Dimer at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of D-Dimer

Interventionug/mL (Mean)
High Risk2.99
Low Risk1.87

The Value of Factor VIIa (FVIIa) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of FVIIa at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of FVIIa

InterventionpM (Mean)
High Risk151.2
Low Risk148.6

The Value of Human F12 at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of Human F12 at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of Human F12

Interventionng/mL (Mean)
High Risk484.7
Low Risk306.3

The Value of Thrombin Antithrombin (TAT) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of TAT at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TAT

Interventionug/L (Mean)
High Risk9.89
Low Risk12.44

The Value of Tissue Factor (TF) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of Tissue Factor at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients. (NCT00876915)
Timeframe: baseline value of tissue factor

Interventionpg/mL (Mean)
High Risk0.669
Low Risk0.187

The Value of Tissue Factor Pathway Inhibitor (TFPI) at Baseline Prior to Chemotherapy in Ambulatory Cancer Patients

Blood samples were obtained to measure the value of TFPI at baseline compared between high risk for VTE and low risk for VTE ambulatory cancer patients (NCT00876915)
Timeframe: baseline value of TFPI

Interventionpg/mL (Mean)
High Risk813.6
Low Risk738.2

Arterial Puncture

Percentage of participants with Arterial puncture aspiration (NCT02318940)
Timeframe: intraoperative, an average of 1 hour

Interventionpercentage of participants (Number)
Landmark Method25
Ultrasound Method10

Installation on the First Try

Percentage of Participants with successful installation on the first transcutaneous passage of the glass needle (NCT02318940)
Timeframe: intraoperative, an average of 1 hour

Interventionpercentage of participants (Number)
Landmark Method18
Ultrasound Method42

Successful Installation

Percentage of participants with successful installation of guide without difficulty in the femoral vein (NCT02318940)
Timeframe: intraoperative, an average of 1 hour

Interventionpercentage of participants (Number)
Landmark Method51
Ultrasound Method84

Number of Attempts

Number of participants who succeeded in the installation of cvc in one, two, three, four or five attempts. (NCT02318940)
Timeframe: intraoperative, an average of 1 hour

,
Interventionparticipants (Number)
first attemptsecond attemptthird attemptfourth attemptfifth attemptUnsuccessful cannulation
Landmark Method9462424
Ultrasound Method21184007

Reviews

30 reviews available for dalteparin and Benign Neoplasms

ArticleYear
Bemiparin in oncology.
    Drugs, 2010, Dec-14, Volume: 70 Suppl 2

    Topics: Anticoagulants; Antineoplastic Agents; Chemotherapy, Adjuvant; Fibrinolytic Agents; Heparin, Low-Mol

2010
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Annals of internal medicine, 2023, Volume: 176, Issue:1

    Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Enoxaparin;

2023
Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.
    Medicine, 2018, Volume: 97, Issue:31

    Topics: Anticoagulants; Enoxaparin; Humans; Neoplasms; Rivaroxaban; Venous Thromboembolism

2018
Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Humans; Neopl

2014
Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome?
    Current opinion in anaesthesiology, 2011, Volume: 24, Issue:2

    Topics: Anticoagulants; Bariatric Surgery; Enoxaparin; Guidelines as Topic; Humans; Neoplasms; Perioperative

2011
Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:2

    Topics: Clinical Trials as Topic; Drug Administration Schedule; Enoxaparin; Humans; Neoplasms; Treatment Out

2012
Venous thromboembolism in cancer patients: expanding horizons.
    Seminars in thrombosis and hemostasis, 2002, Volume: 28 Suppl 3

    Topics: Antineoplastic Agents; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-

2002
Prolonged prophylaxis against postoperative venous thromboembolism.
    Haemostasis, 1996, Volume: 26 Suppl 4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad

1996
Prophylaxis of venous thromboembolism in medical patients.
    Current opinion in pulmonary medicine, 2001, Volume: 7, Issue:5

    Topics: Anticoagulants; Bandages; Brain Ischemia; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Myocard

2001
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Medicina (Kaunas, Lithuania), 2023, Oct-20, Volume: 59, Issue:10

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism

2023
[Direct oral anticoagulants in the treatment of cancer-associated thrombosis].
    Revue medicale suisse, 2019, Dec-04, Volume: 15, Issue:674

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms;

2019
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
    Mayo Clinic proceedings, 2022, Volume: 97, Issue:2

    Topics: Administration, Oral; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans;

2022
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
    The Cochrane database of systematic reviews, 2018, 01-24, Volume: 1

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Heparin, Low-Mol

2018
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Thrombosis research, 2019, Volume: 180

    Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Factor Xa Inhibitors; Humans; Neoplasms; Pyridine

2019
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    The Cochrane database of systematic reviews, 2014, Jun-19, Issue:6

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh

2014
Management of venous thromboembolism in patients with cancer: role of dalteparin.
    Vascular health and risk management, 2008, Volume: 4, Issue:2

    Topics: Anticoagulants; Dalteparin; Drug Costs; Humans; Neoplasms; Quality of Life; Risk Factors; Treatment

2008
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    The Cochrane database of systematic reviews, 2011, Feb-16, Issue:2

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh

2011
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    The Cochrane database of systematic reviews, 2011, Apr-13, Issue:4

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neo

2011
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Anticoagulants; Dalteparin; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weigh

2011
Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review.
    Archives of internal medicine, 2003, Sep-08, Volume: 163, Issue:16

    Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Critical Illness; Dalteparin

2003
Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    European journal of medical research, 2004, Apr-30, Volume: 9, Issue:4

    Topics: Anticoagulants; Blood Coagulation; Coronary Disease; Dalteparin; Heparin, Low-Molecular-Weight; Huma

2004
Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    The journal of supportive oncology, 2006, Volume: 4, Issue:3

    Topics: Anticoagulants; Dalteparin; Evidence-Based Medicine; Humans; Neoplasms; Thromboembolism; Venous Thro

2006
Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.
    International journal of clinical practice, 2022, Volume: 2022

    Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Renal Insufficiency; Thrombosis; Tinzaparin

2022
The Role of Tinzaparin in Oncology.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:5

    Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Treat

2018
Treatment of venous thromboembolism with tinzaparin in oncological patients.
    Minerva medica, 2019, Volume: 110, Issue:3

    Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Tinzaparin; Venous Thromboembolism

2019
Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:2

    Topics: Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Randomized Contro

2018
Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients.
    Thrombosis research, 2012, Volume: 130, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans;

2012
Extending the role of antithrombotic agents: an example based on the low-molecular-weight heparin, tinzaparin.
    Seminars in thrombosis and hemostasis, 2004, Volume: 30 Suppl 1

    Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Thrombosis; Tinzaparin

2004
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    The Cochrane database of systematic reviews, 2014, Aug-29, Issue:8

    Topics: Adult; Ambulatory Care; Anticoagulants; Antineoplastic Agents; Antithrombins; Child; Hemorrhage; Hep

2014
Semuloparin for the prevention of venous thromboembolic events in cancer patients.
    Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:7

    Topics: Animals; Blood Coagulation; Evidence-Based Medicine; Fibrinolytic Agents; Heparin, Low-Molecular-Wei

2012

Trials

67 trials available for dalteparin and Benign Neoplasms

ArticleYear
The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?
    Blood, 2014, Jul-03, Volume: 124, Issue:1

    Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Neoplasms

2014
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
    The Lancet. Oncology, 2009, Volume: 10, Issue:10

    Topics: Aged; Antineoplastic Agents; Cohort Studies; Double-Blind Method; Factor Xa Inhibitors; Female; Fibr

2009
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung

2011
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
    Journal of translational medicine, 2011, Oct-20, Volume: 9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplat

2011
Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
    Haematologica, 2003, Volume: 88, Issue:1

    Topics: Aged; Anticoagulants; Catheterization, Central Venous; Female; Heparin, Low-Molecular-Weight; Humans

2003
Thrombosis prophylaxis in cancer patients with a central venous catheter.
    Archives of internal medicine, 2004, Feb-23, Volume: 164, Issue:4

    Topics: Anticoagulants; Catheterization, Central Venous; Humans; Nadroparin; Neoplasms; Pilot Projects; Pros

2004
The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Humans; Inj

2005
The prognostic value of the D-dimer test in cancer patients treated with and without low-molecular-weight heparin.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:7

    Topics: Anticoagulants; Blood Coagulation Tests; Fibrin Fibrinogen Degradation Products; Humans; Nadroparin;

2005
Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008, Volume: 16, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Neoplasms; P

2008
Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Heparin, Low-Molecular-Weight; Humans;

2010
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial.
    Blood advances, 2020, 05-26, Volume: 4, Issue:10

    Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous Thromboembolism

2020
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
    Vascular, 2021, Volume: 29, Issue:5

    Topics: Administration, Oral; Aged; Anticoagulants; Egypt; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrh

2021
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.
    JAMA neurology, 2018, 03-01, Volume: 75, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Enoxaparin; Female; Fibrinolyti

2018
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    American journal of hematology, 2019, Volume: 94, Issue:11

    Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Human

2019
Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.
    Anti-cancer drugs, 2015, Volume: 26, Issue:1

    Topics: Aged; Aged, 80 and over; Enoxaparin; Factor Xa; Female; Glucuronidase; Humans; Male; Middle Aged; Ne

2015
Independent predictors of poor vitamin K antagonist control in venous thromboembolism patients. Data from the EINSTEIN-DVT and PE studies.
    Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6

    Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Fe

2015
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:12

    Topics: Aged; Anticoagulants; Chi-Square Distribution; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors

2015
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Black or Africa

2016
The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:1

    Topics: Aged; Blood Coagulation; Drug Dosage Calculations; Enoxaparin; Female; Fibrin Fibrinogen Degradation

2010
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).
    British journal of haematology, 2013, Volume: 160, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Cell-Derived Microparticles; Enoxaparin; Female; Fibrin Fib

2013
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2003, Volume: 14, Issue:4

    Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B

2003
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adult; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Chi-Square Distributi

2005
Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2006, Volume: 12, Issue:4

    Topics: Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enoxaparin

2006
[Low molecular-weight heparin (clexane) in the prevention of thrombotic events in patients with malignancies].
    Klinicheskaia laboratornaia diagnostika, 2006, Issue:8

    Topics: Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Care; Postoperative Comp

2006
Prolonged prophylaxis against postoperative venous thromboembolism.
    Haemostasis, 1996, Volume: 26 Suppl 4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Disease Susceptibility; Double-Blind Method; Drug Ad

1996
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
    The New England journal of medicine, 2001, Mar-01, Volume: 344, Issue:9

    Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, L

2001
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.
    BMC cancer, 2011, Jul-26, Volume: 11

    Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin,

2011
Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy.
    Thrombosis and haemostasis, 2005, Volume: 94, Issue:4

    Topics: Anticoagulants; Cause of Death; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle

2005
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:5

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembol

2022
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Chest, 2022, Volume: 161, Issue:3

    Topics: Aged; Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pulm

2022
A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:8

    Topics: Adolescent; Anticoagulants; Child; Dalteparin; Hemorrhage; Humans; Neoplasms; Prospective Studies; V

2022
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    The New England journal of medicine, 2020, 04-23, Volume: 382, Issue:17

    Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec

2020
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
    BMJ open, 2020, 11-19, Volume: 10, Issue:11

    Topics: Aged; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Humans; Male; Neoplasms; Netherland

2020
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 148

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Drug Therapy, Comb

2021
Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
    Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:11

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasm Recurrence, Local; Neoplasms; Venous Thromb

2021
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial
    Haematologica, 2022, 07-01, Volume: 107, Issue:7

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Kidney; Neoplasms; Pyrazoles; Pyridones; Venous Thro

2022
Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Anticoagulants; Canada; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Neoplasm

2017
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
    The New England journal of medicine, 2018, Feb-15, Volume: 378, Issue:7

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weigh

2018
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 07-10, Volume: 36, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Fibrinolyt

2018
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:8

    Topics: Aged; Anticoagulants; Clinical Decision-Making; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage

2018
Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:9

    Topics: Acute Disease; Administration, Oral; Adult; Anticoagulants; Dalteparin; Europe; Follow-Up Studies; H

2018
Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.
    Palliative medicine, 2019, Volume: 33, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibito

2019
Low-molecular-weight-heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study.
    Journal of thrombosis and thrombolysis, 2019, Volume: 47, Issue:4

    Topics: Aged; Coumarins; Dalteparin; Disease-Free Survival; Female; Hemorrhage; Humans; Male; Middle Aged; N

2019
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
    Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:11

    Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem

2019
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:6

    Topics: Aged; Anticoagulants; Canada; Dalteparin; Drug Administration Schedule; Europe; Female; Hemorrhage;

2015
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
    Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6

    Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne

2015
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.
    Journal of thrombosis and thrombolysis, 2016, Volume: 42, Issue:4

    Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Fem

2016
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
    Thrombosis research, 2017, Volume: 151

    Topics: Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Treatmen

2017
Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:12

    Topics: Acenocoumarol; Aged; Anticoagulants; Catheterization, Central Venous; Dalteparin; Female; Humans; Ma

2009
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female;

2003
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, May-15, Volume: 22, Issue:10

    Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Double-Blind Metho

2004
Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.
    British journal of cancer, 2004, Jul-05, Volume: 91, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin-Convertin

2004
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Coumarins; Dalteparin; Female; Heparin, L

2005
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients.
    Thrombosis and haemostasis, 2005, Volume: 93, Issue:6

    Topics: Adult; Aged; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Ne

2005
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Catheters, Indwelling; Dalte

2006
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
    Mayo Clinic proceedings, 2006, Volume: 81, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Double-Blind Method; Female; Humans; Inj

2006
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).
    Thrombosis and haemostasis, 1996, Volume: 75, Issue:2

    Topics: Adult; Aged; Anticoagulants; Arm; Catheterization, Central Venous; Dalteparin; Female; Humans; Incid

1996
Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:8

    Topics: Aged; Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective

2022
Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:6

    Topics: Aged; Anticoagulants; Drug Monitoring; Female; Hemorrhage; Humans; Incidence; International Normaliz

2018
Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous Thromboembolism-Analysis of the CATCH Study.
    Thrombosis and haemostasis, 2018, Volume: 118, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Fibrinolytic Agent

2018
CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
    BMC cancer, 2013, Jun-13, Volume: 13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Heparin, Low-

2013
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    JAMA, 2015, Aug-18, Volume: 314, Issue:7

    Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma

2015
Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Aged; Biomarkers; C-Reactive Protein; Factor VIII; Fibrin Fibrinogen Degradation Products; Fibrinoly

2017
A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2009, Volume: 37, Issue:3

    Topics: Acenocoumarol; Administration, Oral; Age Factors; Anticoagulants; Female; Fibrin Fibrinogen Degradat

2009
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
    The American journal of medicine, 2006, Volume: 119, Issue:12

    Topics: Adult; Aged; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged;

2006
[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013, Volume: 189, Issue:6

    Topics: Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weig

2013
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Adult; Antineoplastic Agents; Double-Blind Method; Fibrinolytic Agents; Fibrinopeptide A; Hemorrhage

2012

Other Studies

81 other studies available for dalteparin and Benign Neoplasms

ArticleYear
[Determination of anti-Xa activity in cancer patients].
    Klinicheskaia laboratornaia diagnostika, 2008, Issue:11

    Topics: Anticoagulants; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Humans; Nadroparin; Neoplasms; Thrombo

2008
Prophylactic plasma levels of the low molecular weight heparin nadroparin does not affect colon cancer tumor development in mouse liver.
    Thrombosis research, 2010, Volume: 125, Issue:3

    Topics: Animals; Heparin, Low-Molecular-Weight; Mice; Mice, Inbred C57BL; Nadroparin; Neoplasms

2010
Thromboprophylaxis during chemotherapy in patients with advanced cancer.
    Thrombosis research, 2010, Volume: 125 Suppl 2

    Topics: Anticoagulants; Antineoplastic Agents; Humans; Nadroparin; Neoplasms; Pulmonary Embolism; Randomized

2010
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
    Internal and emergency medicine, 2012, Volume: 7, Issue:3

    Topics: Antineoplastic Agents; Confidence Intervals; Fibrinolytic Agents; Health Status Indicators; Humans;

2012
Targeted prophylaxis in cancer: the evidence accumulates.
    Internal and emergency medicine, 2013, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Nadroparin; Neoplasms; Risk Assessment; Venous T

2013
Thromboprophylaxis during chemotherapy after advanced cancer.
    Thrombosis research, 2007, Volume: 120 Suppl 2

    Topics: Anticoagulants; Antineoplastic Agents; Humans; Nadroparin; Neoplasms; Randomized Controlled Trials a

2007
[The impact of hemodilution and low-molecular-weight fraxiparin on volumetric indexes and frequency of postoperative complications in surgical treatment of patients with oncological diseases].
    Klinichna khirurhiia, 2001, Issue:3

    Topics: Anticoagulants; Hemodilution; Hypovolemia; Molecular Weight; Nadroparin; Neoplasms; Postoperative Co

2001
Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Aged; Anticoagulants; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Human

2020
Effect of adding bemiparin and cefepime to routine treatment in cancer patients with SARS-CoV-2 infection.
    Medicina clinica, 2021, 09-24, Volume: 157, Issue:6

    Topics: Cefepime; COVID-19; Heparin, Low-Molecular-Weight; Humans; Neoplasms; SARS-CoV-2

2021
Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:4

    Topics: Aged; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; P

2020
[Role of low molecular weight heparins in prophylaxis of thromboembolic events on oncological patients with indwelling central venous catheter].
    Medicina clinica, 2009, Sep-19, Volume: 133, Issue:10

    Topics: Adult; Aged; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Data Interpreta

2009
Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
    International journal of surgery (London, England), 2007, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug A

2007
Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:12

    Topics: Anticoagulants; Child; Enoxaparin; Humans; Neoplasms; Thrombosis; Vena Cava, Superior; Venous Thromb

2021
A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2022, Apr-01, Volume: 33, Issue:3

    Topics: Anticoagulants; Catheters; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pilot Projects; Postthrombotic

2022
Assessing the use of Extended Venous Thromboembolism Prophylaxis on the Rates of Venous Thromboembolism and Postpancreatectomy Hemorrhage Following Pancreatectomy for Malignancy.
    Annals of surgery, 2023, Jul-01, Volume: 278, Issue:1

    Topics: Aftercare; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Neoplasms; Pancreatectomy; Patient Discha

2023
Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients.
    Journal of pediatric hematology/oncology, 2023, 01-01, Volume: 45, Issue:1

    Topics: Administration, Oral; Adult; Anticoagulants; Child; Enoxaparin; Hemorrhage; Humans; Neoplasms; Venou

2023
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
    Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:1

    Topics: Anticoagulants; Catheters; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans;

2023
Time to rethink extended thromboprophylaxis after cancer surgery?
    Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:2

    Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Complica

2023
Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin.
    Journal of thrombosis and thrombolysis, 2020, Volume: 50, Issue:1

    Topics: Anticoagulants; Biomarkers, Pharmacological; Blood Coagulation; Body Weight; Drug Dosage Calculation

2020
Apixaban vs Enoxaparin for Postoperative Prophylaxis: Safety of an Oral Alternative for the Prevention of Venous Thromboembolism.
    JAMA network open, 2020, 06-01, Volume: 3, Issue:6

    Topics: Enoxaparin; Female; Humans; Neoplasms; Pyrazoles; Pyridones; Venous Thromboembolism

2020
Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:9

    Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Neoplasms;

2021
Anticoagulant therapy management of venous thromboembolism recurrence occurring during anticoagulant therapy: a descriptive study.
    Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:2

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Middle Aged; Neoplasms; Recurrence

2021
Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer.
    European journal of internal medicine, 2021, Volume: 89

    Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Enoxaparin; Heparin, Low-Molecular-Weight

2021
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Hepar

2018
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2017, Volume: 26, Issue:12

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Daltep

2017
Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:3

    Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; H

2018
Anticoagulation prescribing patterns in patients with cancer.
    Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1

    Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle

2018
Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study.
    Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2018, Volume: 14, Issue:4

    Topics: Adult; Aged; Anticoagulants; Bariatric Surgery; Drug Therapy, Combination; Enoxaparin; Epidemiologic

2018
Prophylactic enoxaparin doses may be inadequate in patients undergoing abdominal cancer surgery.
    The Journal of surgical research, 2018, Volume: 221

    Topics: Abdomen; Anticoagulants; Chemoprevention; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Mi

2018
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:3

    Topics: Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Age

2018
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Vascular pharmacology, 2019, Volume: 120

    Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabig

2019
Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Apr-01, Volume: 71, Issue:7

    Topics: Anticoagulants; Cohort Studies; Enoxaparin; Female; Health Care Costs; Heparin; Humans; Injections;

2014
Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Fo

2016
Venous Thromboembolism after Allogeneic Pediatric Hematopoietic Stem Cell Transplantation: A Single-Center Study.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3

    Topics: Activated Protein C Resistance; Adolescent; Allografts; Catheterization, Central Venous; Child; Chil

2015
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.
    Blood, 2015, Jul-23, Volume: 126, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Boston; Brain Neoplasms; Case-Control Studies; Enoxa

2015
Balancing bleeding in brain metastases.
    Blood, 2015, Jul-23, Volume: 126, Issue:4

    Topics: Anticoagulants; Brain Neoplasms; Enoxaparin; Female; Humans; Intracranial Hemorrhages; Male; Neoplas

2015
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:9

    Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Fondaparinux; Heparin;

2015
Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2017, Volume: 23, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Age

2017
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.
    Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:4

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Guideline Adherence; Hemorrhage; Humans; Male; Neoplasms;

2017
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu

2009
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F

2010
Use of deep vein thrombosis prophylaxis in hospitalized cancer patients.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:7

    Topics: Adult; Aged; Anticoagulants; Contraindications; Enoxaparin; Female; Humans; Inpatients; Male; Medica

2009
Optimal duration of anticoagulation after venous thromboembolism.
    Circulation, 2011, Feb-15, Volume: 123, Issue:6

    Topics: Aged; Altitude Sickness; Anticoagulants; Cholesterol, HDL; Clinical Trials as Topic; Enoxaparin; Fem

2011
Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge.
    The American journal of medicine, 2011, Volume: 124, Issue:12

    Topics: Aged; Anticoagulants; Case-Control Studies; Confidence Intervals; Endpoint Determination; Enoxaparin

2011
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio

2012
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.
    Bone marrow transplantation, 2005, Volume: 35, Issue:11

    Topics: Adult; Aged; Anticoagulants; Blood Platelets; Bone Marrow Transplantation; Cohort Studies; Enoxapari

2005
[Administration of clexane 4000 U/0.4 ml (40 mg) for preventing venous thromboembolic complications in patients undergoing surgery for malignant tumors. A follow-up study].
    Magyar sebeszet, 2005, Volume: 58, Issue:3

    Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Inc

2005
Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2007, Volume: 13, Issue:2

    Topics: Adolescent; Blood Coagulation Disorders; Child; Child, Preschool; Enoxaparin; Female; Humans; Male;

2007
Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2007, Volume: 18, Issue:4

    Topics: Alanine; Cell Line, Tumor; Drug Therapy, Combination; Enoxaparin; Heparin, Low-Molecular-Weight; Hum

2007
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients.
    Internal and emergency medicine, 2008, Volume: 3, Issue:2

    Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Catheters, Indwelling; Confi

2008
Low-molecular-weight heparin in the management of Trousseau's syndrome.
    Cancer, 1997, Aug-15, Volume: 80, Issue:4

    Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Neoplasms; Paraneoplastic Synd

1997
Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense?
    The Netherlands journal of medicine, 2000, Volume: 56, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Incidence; Male; Neoplasms;

2000
[Possible effect low molecular weight heparin on survival time. New chances for cancer patients?].
    MMW Fortschritte der Medizin, 2003, May-08, Volume: 145, Issue:19

    Topics: Anticoagulants; Clinical Trials as Topic; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Injecti

2003
Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 165

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Neoplasms, Second Primary; Venous Thrombo

2022
[Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive?]
    Zeitschrift fur Gastroenterologie, 2023, Volume: 61, Issue:4

    Topics: Anticoagulants; Dalteparin; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Neoplasms; Pr

2023
[Antithrombotic Treatment of Pulmonary Embolism].
    Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:14

    Topics: Acute Disease; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fibrinoly

2020
[Toward the use of direct oral anticoagulants as a first line therapy in cancer-associated venous thromboembolism].
    La Revue de medecine interne, 2020, Volume: 41, Issue:9

    Topics: 4-Hydroxycoumarins; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Hemo

2020
In cancer-associated VTE, apixaban was noninferior to dalteparin for recurrence and did not increase major bleeding.
    Annals of internal medicine, 2020, 08-18, Volume: 173, Issue:4

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Humans; Neoplasms; Pyrazoles; Pyridones; Recurrence; Venous

2020
Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2021, Volume: 31, Issue:3

    Topics: Anticoagulants; Dalteparin; Female; Humans; Neoplasms; Retrospective Studies; Rivaroxaban; Venous Th

2021
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:9

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H

2018
[Treatment of cancer-associated venous thromboembolism].
    Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:9 Suppl 1

    Topics: Anticoagulants; Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Practice G

2018
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
    Journal of thrombosis and thrombolysis, 2019, Volume: 48, Issue:3

    Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Gastrointestinal Neoplasms; Humans; Markov Chains

2019
VTE and anti-coagulation therapy in cancer patients.
    European heart journal. Cardiovascular pharmacotherapy, 2019, 10-01, Volume: 5, Issue:4

    Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dalteparin; Factor Xa Inhibitors; Human

2019
Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Blood Transfusion; Dalteparin; Female; Fibrinolytic Agents; Hospital

2014
Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:7

    Topics: Anticoagulants; Austria; Cost-Benefit Analysis; Dalteparin; Female; France; Humans; Male; Middle Age

2017
Cancer-associated thrombosis.
    The New England journal of medicine, 2003, Jul-10, Volume: 349, Issue:2

    Topics: Anticoagulants; Dalteparin; Humans; Neoplasms; Pulmonary Embolism; Risk Factors; Secondary Preventio

2003
Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Agents; Catheterization, Central Veno

2004
[Initial trials give hope. Anticoagulants against cancer?].
    MMW Fortschritte der Medizin, 2003, Apr-03, Volume: 145, Issue:14

    Topics: Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Fibrinolytic Agents; Heparin; Human

2003
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
    Journal of thrombosis and haemostasis : JTH, 2004, Volume: 2, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor

2004
Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
    Cancer letters, 2005, Mar-10, Volume: 219, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Captopril; Dalteparin; Female; Humans; Hydroxa

2005
Catheter-related clotting not reduced by dalteparin.
    The Lancet. Oncology, 2006, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Clinical Trials, Phase III as

2006
Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    PharmacoEconomics, 2006, Volume: 24, Issue:6

    Topics: Adult; Anticoagulants; Canada; Dalteparin; Female; Humans; Male; Middle Aged; Neoplasms; Quality of

2006
A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:8

    Topics: Aged; Anticoagulants; Catheterization, Central Venous; Cohort Studies; Dalteparin; Female; Humans; I

2007
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
    Thrombosis and haemostasis, 1999, Volume: 82, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Arm; Catheterization, Central Venous; C

1999
Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study.
    Journal de medecine vasculaire, 2022, Volume: 47, Issue:2

    Topics: Heparin, Low-Molecular-Weight; Humans; Neoplasms; Prospective Studies; Thrombosis; Tinzaparin; Venou

2022
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:1

    Topics: Adult; Aged; Anticoagulants; Cohort Studies; Female; Follow-Up Studies; France; Humans; Male; Middle

2022
Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
    Thrombosis research, 2017, Volume: 157

    Topics: Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pr

2017
Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
    Thrombosis research, 2015, Volume: 135, Issue:1

    Topics: Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-W

2015
The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm.
    American journal of hematology, 2017, Volume: 92, Issue:6

    Topics: Adult; Aged; Anticoagulants; Antineoplastic Agents; Control Groups; Controlled Clinical Trials as To

2017
Routine heparin for patients with cancer? One answer, more questions.
    The New England journal of medicine, 2012, Feb-16, Volume: 366, Issue:7

    Topics: Fibrinolytic Agents; Fibrinopeptide A; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous Thro

2012
Semuloparin helps prevent thromboembolic events in patients receiving chemotherapy.
    Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Venous

2012